Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Keith S. Kaye, MD, MPH; Lilian Abbo, MD, FIDSA; and Jason M. Pogue, PharmD, discuss HABP/VABP and gram-negative resistance including:
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey
Associate Chief Medical Officer in Infectious Diseases
Jackson Health System
Professor of Infectious Diseases
Department of Medicine & Miami Transplant Institute
University of Miami Miller School of Medicine
Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Infectious Diseases Clinical Pharmacist
Ann Arbor, Michigan
This program has been made available online.
Expert faculty discuss ways to improve the empiric treatment of HABP/VABP in the ICU in this commentary from Clinical Care Options (CCO)
Learn from experts about strategies to improve timely, effective antibiotic therapy in patients with HABP/VABP at risk for multidrug resistance, from Clinical Care Options (CCO)
Hear experts discuss ExPEC burden, populations at risk and potential vaccines to reduce invasive disease and antibiotic resistance, from Clinical Care Options (CCO).
Clinical Care Options (CCO) presents expert faculty discussing RSV in certain adult populations and the development of RSV vaccines